https://www.selleckchem.com/pr....oducts/cathepsin-g-i
8% vs. 85.1%; C 74.9% vs. 62.8%) and distinctly higher than after MPSV4 for serogroups W and Y (W 79.5% vs. 60.6%; Y 80.5% vs. 59.6%). Proportions of participants with rSBA titers ≥18 were comparable between vaccine groups for all four serogroups. The reactogenicity profiles of both vaccines were similar. Most unsolicited adverse events (AEs) were of Grade 1 or Grade 2 intensity, and no serious AEs were reported. The MenACYW-TT conjugate vaccine was well tolerated and immunogenic in adults aged ≥56 y.Phyllachora maydis i
Like
Comment
Share
